4.4 Article

Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/NFκB and AP-1 in the human breast cancer cell line MDA-MB-231

Journal

ANTI-CANCER DRUGS
Volume 21, Issue 6, Pages 632-644

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CAD.0b013e32833a4385

Keywords

AP1; breast cancer; epigallocatechin-3-gallate; extracellular regulated kinase; focal adhesion kinase; integrins; matrix-metalloproteinase-9; nuclear factor kappa B

Funding

  1. Chittaranjan National Cancer Institute
  2. National Tea Research Foundation [RL: 17(75)/2004]

Ask authors/readers for more resources

Epigallocatechin-3-gallate (EGCG) is effective against the initiation, progression, and invasion of carcinogenesis. Matrix-metalloproteinases (MMPs) are a family of endopeptidases that hydrolyze the majority of extracellular proteins. MMP-9 is one of the most important members of the family and we observed the effect of EGCG on MMP-9 in the human breast cancer cell line, MDA-MB-231. The effect of EGCG on MMP-9 was studied by gelatin zymography, western blot, quantitative and semiquantitative real-time RT-PCR, immunoflourescence, cell adhesion assay, enzyme-linked immunosorbent assay, and electrophoretic mobility shift assay. EGCG treatment reduced the activity, protein, and mRNA expression of MMP-9 and enhanced the expression of the tissue inhibitor of MMP 1 (TIMP-1). EGCG downregulated the activation of focal adhesion kinase (FAK) and extracellular regulated kinase (ERK), reduced the adhesion of MDA-MB-231 cells to fibronectin and vitronectin, and reduced the mRNA expression of the integrin receptors alpha 5 beta 1 and alpha v beta 3. The expression of the nuclear factor kappa B (NF kappa B), and the DNA binding activity of NF kappa B and activator protein 1 (AP1) to MMP-9 promoter were noticeably reduced on EGCG treatment. Upregulation of TIMP-1 and disruption of the functional status of integrin receptors may indicate decreased MMP-9 activation; inhibition of FAK and ERK activation might indicate disruption in the FAK/ERK-induced MMP-9 secretion and induction. Decreased DNA binding activity of NF kappa B and AP1 to MMP-9 promoter might indicate transcriptional deregulation of MMP-9 gene on EGCG treatment. We propose EGCG as a potential inhibitor of the expression and activity of MMP-9 by a process involving FAK/ERK and transcription factors in MDA-MB-231. Anti-Cancer Drugs 21:632-644 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available